Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor Positive Tumor|Metastatic Breast Cancer
Interventions: DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Pegylated liposomal doxorubicin|DRUG: Cyclophosphamide
Sponsor: Oslo University Hospital
Collaborators: Bristol-Myers Squibb|Helse Stavanger HF|Helse Sor-Ost|Sorlandet Hospital HF|Jules Bordet Institute|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Centre Hospitalier Universitaire UCLouvain Namur